Topotarget will need different competences
If the FDA approval of main asset Beleodaq comes together, Topotarget will need a number of new employees over the coming years. Moreover, the company’s new strategy shows that the tactical M&A game has begun.
by Stefan Singh Kailay
A lot will be decided for the Danish company Topotarget come August. At this time, the American approval agency FDA will decide whether or not to green-light the company’s main asset Beleodaq for the US market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Topotarget CEO: It actually saves us money
For abonnenter
